Levonorgestrel- and ulipristal acetate-containing medicines for emergency contraception: influence of body weight/BMI on efficacy/bioavailability
2014.11.07
Active substance: levonorgestrel | ulipristal acetate
7.11.2014 - Notice within the graduated plan procedure ("Stufenplanverfahren")
In its notice of 5 November 2014, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the realisation of the corresponding implementing decision C(2014)7147of the EU Commission.
24.07.2014 - CHMP opinion
The European Medicines Agency has concluded its review of emergency contraceptives containing levonorgestrel or ulipristal acetate.
For further information click on the following link:
24.01.2014 - Procedure started
The BfArM issues information on the initiation of a European review in accordance with Article 31 of Directive 2001/83/EC
Further information
For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):
To the risk assessment procedure (available in German only)